Scotland Becomes First Part Of UK To Screen Newborns For Spinal Muscular Atrophy

Scotland becomes first part of UK to screen newborns for Spinal Muscular Atrophy Scotland has become the first part of the United Kingdom to introduce routine newborn screening for Spinal Muscular Atrophy (SMA) as part of standard post‑birth checks, a move campaigners hope will save lives and prompt similar programmes across the rest of the UK.

Under the new pilot programme, all newborn babies in Scotland are offered SMA testing through the existing heel prick blood test taken around four days after birth, enabling earlier detection of the condition before symptoms develop.

SMA is a rare genetic neuromuscular disorder that affects motor nerve cells in the spinal cord, leading to progressive muscle weakness and difficulty with movement, breathing and swallowing. Without early intervention, the most severe form SMA type 1 can be fatal, with many infants not surviving past age two. Early diagnosis through newborn screening is critical because available treatments including gene therapies and medications that can slow or halt disease progression are most effective if given before symptoms start. Detecting the condition at birth allows clinicians to begin treatment sooner, improving outcomes and potentially extending quality of

The newborn screening pilot in Scotland is funded jointly by the Scottish government and pharmaceutical company Novartis and is expected to run for two years. The goal is to gather evidence on the effectiveness of routine SMA screening to inform longer‑term decisions.

• All babies born in Scotland are now offered SMA screening via the routine bloodspot test.
• Any baby who tests positive will receive early clinical follow‑up and access to NHS‑funded treatments a step change from past practice, when many babies were diagnosed only after symptoms appeared.
• Data from the programme will be used to support advice from the UK National Screening Committee (UK NSC) on whether SMA screening should be adopted across the whole UK.

On average, three to four babies are born with SMA each year in Scotland, according to charity and health officials.

Campaigners have long pushed for newborn SMA screening in the UK, arguing that early detection can make a life‑changing difference for affected families. The issue gained widespread attention earlier this year after former Little Mix singer Jesy Nelson revealed that her twin daughters were diagnosed with SMA type 1, highlighting the challenges of later‑stage diagnosis and rallying public support for screening. Her petition calling for SMA to be added to routine newborn checks in England gathered more than 100,000 signatures and was debated in the UK Parliament. Supporters of Scotland’s new programme say the results could provide critical evidence to the UK NSC and serve as a model for England, Wales and Northern Ireland, where SMA screening has not yet been rolled out as standard practice. Health leaders emphasise that while SMA is rare affecting around 1 in 14,000 births worldwide the impact of early detection on treatment outcomes can be profound. With three NHS‑funded treatments now available in Scotland, the combination of screening and timely therapy could dramatically change prospects for affected infants. Officials say the data collected during the pilot will be shared with health authorities across the UK, helping inform a UK‑wide policy decision on whether to adopt newborn SMA screening more broadly. Spinal Muscular Atrophy is caused by mutations in the SMN1 gene, which lead to a shortage of the survival motor neuron (SMN) protein. This deficiency results in the loss of motor neurons nerve cells that control voluntary muscles leading to the hallmark symptoms of the condition. Newborn screening for SMA already standard in parts of the United States and some other countries aims to identify affected infants before symptoms begin, enabling early intervention that can preserve motor function and improve survival.